Reproducibility of intracardiac and transpulmonary biomarkers in the evaluation of pulmonary hypertension

Pulmonary Circulation

Volumn 3, Issue 2, 2013, Pages 345-349

  Monahan, Ken ^a   Scott, Theresa A ^a   Su, Yan Ru ^a   Lenneman, Carrie G ^a   Zhao, David X ^a   Robbins, Ivan M ^a   Hemnes, Anna R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cyclic guanosine monophosphate; Natriuretic peptides; Right heart catheterization

Indexed keywords

EID: 84961884482     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.114762     Document Type: Article

References (11)

1. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357-68.
2. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8.
3. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:464-70.
4. Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005;128:2368-74.
5. Nagaya N, Nishikimi T, Uematsu M, Satoh T, Kyotani S, Sakakmaki F, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-70.
6. Fijalkowska A, Kurzyna, M, Torbicki, A, Szewczyk G, Florczyk M, Pruszczyk P, et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006;129:1313-21.
7. Melenovsky V, Al-Hiti H, Kazdova L, Jabor A, Syrovatka P, Malek I, et al. Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension. J Am Coll Cardiol 2009;54:595-600.
8. Richards AM. Variability of NT-proBNP levels in heart failure: Implications for clinical application. Heart 2007;93:899-900.
9. Lainchbury JG, Nicholls MG, Espiner EA, Ikram H, Yandle TG, Richards AM. Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. Clin Sci (Lond) 1998; 95:547-55
10. Goetze JP, Videbaek R, Boesgaard S, Aldershvile J, Rehfeld JF, Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. J Heart Lung Transplant 2004;23:80-7.
11. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006;27:47-72